Base de dados : MEDLINE
Pesquisa : D06.472.931.103 [Categoria DeCS]
Referências encontradas : 183 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 19 ir para página                         

  1 / 183 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27603906
[Au] Autor:Chaker L; Baumgartner C; den Elzen WP; Collet TH; Ikram MA; Blum MR; Dehghan A; Drechsler C; Luben RN; Portegies ML; Iervasi G; Medici M; Stott DJ; Dullaart RP; Ford I; Bremner A; Newman AB; Wanner C; Sgarbi JA; Dörr M; Longstreth WT; Psaty BM; Ferrucci L; Maciel RM; Westendorp RG; Jukema JW; Ceresini G; Imaizumi M; Hofman A; Bakker SJ; Franklyn JA; Khaw KT; Bauer DC; Walsh JP; Razvi S; Gussekloo J; Völzke H; Franco OH; Cappola AR; Rodondi N; Peeters RP; Thyroid Studies Collaboration
[Ad] Endereço:Departments of Internal Medicine (R.P.P., L.C., M.M.) and Epidemiology (R.P.P., O.H.F., A.D., A.H., A.I., L.C., M.L.P.P.), Erasmus University Medical Center, 3000 DR Rotterdam, The Netherlands; Rotterdam Thyroid Center (R.P.P., L.C., M.M.) and Department of Radiology and Neurology (M.A.I.), Erasmus
[Ti] Título:Thyroid Function Within the Reference Range and the Risk of Stroke: An Individual Participant Data Analysis.
[So] Source:J Clin Endocrinol Metab;101(11):4270-4282, 2016 Nov.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONTEXT: The currently applied reference ranges for thyroid function are under debate. Despite evidence that thyroid function within the reference range is related with several cardiovascular disorders, its association with the risk of stroke has not been evaluated previously. DESIGN AND SETTING: We identified studies through a systematic literature search and the Thyroid Studies Collaboration, a collaboration of prospective cohort studies. Studies measuring baseline TSH, free T , and stroke outcomes were included, and we collected individual participant data from each study, including thyroid function measurements and incident all stroke (combined fatal and nonfatal) and fatal stroke. The applied reference range for TSH levels was between 0.45 and 4.49 mIU/L. RESULTS: We collected individual participant data on 43 598 adults with TSH within the reference range from 17 cohorts, with a median follow-up of 11.6 years (interquartile range 5.1-13.9), including 449 908 person-years. Age- and sex-adjusted pooled hazard ratio for TSH was 0.78 (95% confidence interval [CI] 0.65-0.95 across the reference range of TSH) for all stroke and 0.83 (95% CI 0.62-1.09) for fatal stroke. For the free T analyses, the hazard ratio was 1.08 (95% CI 0.99-1.15 per SD increase) for all stroke and 1.10 (95% CI 1.04-1.19) for fatal stroke. This was independent of cardiovascular risk factors including systolic blood pressure, total cholesterol, smoking, and prevalent diabetes. CONCLUSION: Higher levels of TSH within the reference range may decrease the risk of stroke, highlighting the need for further research focusing on the clinical consequences associated with differences within the reference range of thyroid function.
[Mh] Termos MeSH primário: Dextrotireoxina/sangue
Acidente Vascular Cerebral/sangue
Acidente Vascular Cerebral/epidemiologia
Tireotropina/sangue
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Valores de Referência
Risco
Acidente Vascular Cerebral/mortalidade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
4W9K63FION (Dextrothyroxine); 9002-71-5 (Thyrotropin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160908
[St] Status:MEDLINE


  2 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27583471
[Au] Autor:Yang S; Shi FT; Leung PC; Huang HF; Fan J
[Ad] Endereço:International Peace Maternity and Child Health Hospital (S.Y., F.-T.S., H.-F.H., J.F.), School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China; Institute of Embryo-Fetal Original Adult Disease Affiliated to Shanghai Jiao Tong University School of Medicine (F.-T.S., H.-F.H.), Shang
[Ti] Título:Low Thyroid Hormone in Early Pregnancy Is Associated With an Increased Risk of Gestational Diabetes Mellitus.
[So] Source:J Clin Endocrinol Metab;101(11):4237-4243, 2016 Nov.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Although thyroid dysfunction in early pregnancy may have adverse effects on pregnancy outcome and offspring, few prospective studies have evaluated these effects. OBJECTIVE: Our aim was to evaluate the correlations between different thyroid hormone levels in early pregnancy and the incidence of gestational diabetes mellitus (GDM). SETTING AND PARTICIPANTS: The study comprised 27 513 mothers who provided early pregnancy serum samples for analyses of thyroid function. GDM was diagnosed using a 2 hours, 75-g oral glucose tolerance test, and the mothers were grouped and compared according to the results. MAIN OUTCOME MEASURES: We focused on GDM during the index pregnancy. RESULTS: The incidence of GDM in pregnant women tended to increase with age (5.83%, 10.18%, 14.95%, and 22.40%; P < .0001). The incidence of GDM increased with increasing prepregnancy body mass index (P < .0001). Pregnant women with a family history of diabetes had a much higher incidence of GDM than those without a family history of diabetes (21.09% vs 12.92%; P < .0001). The level of free T (FT ) in early pregnancy in GDM women was lower than that in non GDM women (P < .0001). With increasing early pregnancy FT , the rate of incident GDM was decreasing (P < .0001). CONCLUSIONS: Low thyroid hormone levels in early pregnancy are a risk factor for GDM incidence.
[Mh] Termos MeSH primário: Dextrotireoxina/sangue
Diabetes Gestacional/sangue
Diabetes Gestacional/epidemiologia
[Mh] Termos MeSH secundário: Adulto
China/epidemiologia
Feminino
Seres Humanos
Gravidez
Primeiro Trimestre da Gravidez
Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
4W9K63FION (Dextrothyroxine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160902
[St] Status:MEDLINE


  3 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27552542
[Au] Autor:Pearce SH; Razvi S; Yadegarfar ME; Martin-Ruiz C; Kingston A; Collerton J; Visser TJ; Kirkwood TB; Jagger C
[Ad] Endereço:Institute of Genetic Medicine (S.H.S.P., S.R.), Newcastle University, Newcastle upon Tyne NE1 3BZ, United Kingdom; Institute of Health and Society (M.E.Y., C.M.-R., A.K., J.C., T.B.K., C.J.), Newcastle University, Newcastle upon Tyne NE2 4AX, United Kingdom; and Department of Internal Medicine (T.J.
[Ti] Título:Serum Thyroid Function, Mortality and Disability in Advanced Old Age: The Newcastle 85+ Study.
[So] Source:J Clin Endocrinol Metab;101(11):4385-4394, 2016 Nov.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Perturbations in thyroid function are common in older individuals but their significance in the very old is not fully understood. OBJECTIVE: This study sought to determine whether thyroid hormone status and variation of thyroid hormones within the reference range correlated with mortality and disability in a cohort of 85-year-olds. DESIGN: A cohort of 85-year-old individuals were assessed in their own homes (community or institutional care) for health status and thyroid function, and followed for mortality and disability for up to 9 years. SETTING AND PARTICIPANTS: Six hundred and forty-three 85-year-olds registered with participating general practices in Newcastle and North Tyneside, United Kingdom. MAIN OUTCOMES: All-cause mortality, cardiovascular mortality, and disability according to thyroid disease status and baseline thyroid hormone parameters (serum TSH, FT , FT , and rT ). Models were adjusted for age, sex, education, body mass index, smoking, and disease count. RESULTS: After adjustment for age and sex, all-cause mortality was associated with baseline serum rT and FT (both P < .001), but not FT or TSH. After additional adjustment for potential confounders, only rT remained significantly associated with mortality (P = .001). Baseline serum TSH and rT predicted future disability trajectories in men and women, respectively. CONCLUSIONS: Our study is reassuring that individuals age 85 y with both subclinical hypothyroidism and subclinical hyperthyroidism do not have a significantly worse survival over 9 years than their euthyroid peers. However, thyroid function tests did predict disability, with higher serum TSH levels predicting better outcomes. These data strengthen the argument for routine use of age-specific thyroid function reference ranges.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/mortalidade
Pessoas com Deficiência/estatística & dados numéricos
Mortalidade
Doenças da Glândula Tireoide/sangue
Doenças da Glândula Tireoide/epidemiologia
Tireotropina/sangue
Tri-Iodotironina Reversa/sangue
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Dextrotireoxina/sangue
Inglaterra/epidemiologia
Feminino
Seres Humanos
Estudos Longitudinais
Masculino
Valores de Referência
Testes de Função Tireóidea
Tri-Iodotironina/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
06LU7C9H1V (Triiodothyronine); 4W9K63FION (Dextrothyroxine); 5817-39-0 (Triiodothyronine, Reverse); 9002-71-5 (Thyrotropin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160824
[St] Status:MEDLINE


  4 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24920280
[Au] Autor:Unüvar T; Anik A; Catli G; Esen I; Abaci A; Büyükgebiz A; Böber E
[Ad] Endereço:Department of Pediatric Endocrinology, Medical Faculty, Adnan Menderes University, Aydin, 09100, Turkey, tunuvar@gmail.com.
[Ti] Título:Isolated hyperthyrotropinemia in childhood obesity and its relation with metabolic parameters.
[So] Source:J Endocrinol Invest;37(9):799-804, 2014 Sep.
[Is] ISSN:1720-8386
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The aim of the presented study was to evaluate the prevalence of isolated hyperthyrotropinemia (IH) in obese children and the relation between anthropometric and metabolic parameters. METHODS: Hospital records of the children, who presented to the Pediatric Endocrinology outpatient clinic of our institution with obesity, and age and gender-matched healthy children, who had undergone thyroid function test for any reason were retrospectively reviewed. RESULTS: The prevalence of IH was significantly higher in the obese group than in the controls (9.2 and 3.8 %, respectively). Body mass index-standard deviation score (BMI-SDS), thyroid-stimulating hormone (TSH), lipid parameters were significantly different in the obese group than in the control group. A positive correlation between TSH and BMI-SDS and negative correlation between TSH and free T4 (fT4) levels were found in obese subjects. Stepwise multiple linear regression analysis confirmed that BMI-SDS, fT4 and triglyceride levels were the strongest independent variables correlated with TSH level in obese subjects (r (2) = 0.046, p = 0.001). CONCLUSIONS: IH prevalence is higher in obese children as compared to healthy children and the increase in TSH level correlates negatively with serum fT4 and positively with BMI-SDS and triglyceride levels in obese children.
[Mh] Termos MeSH primário: Índice de Massa Corporal
Dextrotireoxina/sangue
Obesidade Pediátrica/metabolismo
Tireotropina/sangue
Triglicerídeos/sangue
[Mh] Termos MeSH secundário: Adolescente
Criança
Feminino
Seres Humanos
Masculino
Obesidade Pediátrica/sangue
Estudos Retrospectivos
Testes de Função Tireóidea
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Triglycerides); 4W9K63FION (Dextrothyroxine); 9002-71-5 (Thyrotropin)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140613
[St] Status:MEDLINE
[do] DOI:10.1007/s40618-014-0100-y


  5 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16698041
[Au] Autor:Kundu S; Pramanik M; Roy S; De J; Biswas A; Ray AK
[Ad] Endereço:Department of Animal Physiology, Bose Institute, P 1/12, CIT Scheme VII M, Calcutta 700054, India.
[Ti] Título:Maintenance of brain thyroid hormone level during peripheral hypothyroid condition in adult rat.
[So] Source:Life Sci;79(15):1450-5, 2006 Sep 05.
[Is] ISSN:0024-3205
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Thyroid hormones are essential for normal functioning of adult mammalian brain. The present investigation deals with the understanding of the time course of thyroid hormone homeostasis in adult rat brain. Animals were rendered hypothyroid by PTU injections (2 mg/100 g bw) for 30 consecutive days. Serum and synaptosomal T3/T4 content, synaptosomal AChE and Na+-K+-ATPase activities were determined on alternate days. While serum T4 level initially increased on the second day compared to control, serum T3 declined in a triphasic pattern; the first phase lasting from the second day to the 6th day, the second phase ended on the 14th day and last phase continued till the 30th day. Cerebro-cortical synaptosomal T3 level increased on the 2nd day from the control, attained a peak on the 4th day, remained stable until the 18th day, and abruptly declined on the 20th day. Synaptosomal T4 content remained negligible or undetected throughout. Synaptosomal membrane Na+-K+-ATPase and AChE activity exhibited an inverse relationship during the experimental regime, being much more prominent on the 2nd, 18th and 20th day coinciding with the variations in brain T3 level. Thus, the study identifies the onset of central homeostasis between the first and second day, its continuation for about 16-18 days and its termination between the 18th and 20th day.
[Mh] Termos MeSH primário: Encéfalo/metabolismo
Dextrotireoxina/metabolismo
Hipotireoidismo/metabolismo
Tri-Iodotironina/metabolismo
[Mh] Termos MeSH secundário: Acetilcolinesterase/análise
Acetilcolinesterase/metabolismo
Animais
Antitireóideos/toxicidade
Química Encefálica
Dextrotireoxina/análise
Dextrotireoxina/sangue
Homeostase
Hipotireoidismo/induzido quimicamente
Masculino
Propiltiouracila/toxicidade
Ratos
Ratos Sprague-Dawley
ATPase Trocadora de Sódio-Potássio/análise
ATPase Trocadora de Sódio-Potássio/metabolismo
Membranas Sinápticas/enzimologia
Sinaptossomos/enzimologia
Tri-Iodotironina/análise
Tri-Iodotironina/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antithyroid Agents); 06LU7C9H1V (Triiodothyronine); 4W9K63FION (Dextrothyroxine); 721M9407IY (Propylthiouracil); EC 3.1.1.7 (Acetylcholinesterase); EC 3.6.3.9 (Sodium-Potassium-Exchanging ATPase)
[Em] Mês de entrada:0610
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060516
[St] Status:MEDLINE


  6 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16617153
[Au] Autor:Visser TJ
[Ad] Endereço:Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. t.j.visser@erasmusmc.nl
[Ti] Título:The elemental importance of sufficient iodine intake: a trace is not enough.
[So] Source:Endocrinology;147(5):2095-7, 2006 May.
[Is] ISSN:0013-7227
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Iodo/fisiologia
Oligoelementos/metabolismo
[Mh] Termos MeSH secundário: Animais
Astrócitos/metabolismo
Transporte Biológico
Hipotireoidismo Congênito/prevenção & controle
Dextrotireoxina/metabolismo
Feminino
Seres Humanos
Iodeto Peroxidase/metabolismo
Iodo/metabolismo
Radioisótopos do Iodo/química
Ferro
Masculino
Modelos Biológicos
Mutação
Necessidades Nutricionais
Gravidez
Cloreto de Sódio na Dieta
Hormônios Tireóideos/metabolismo
Distribuição Tecidual
Tri-Iodotironina/metabolismo
[Pt] Tipo de publicação:COMMENT; NEWS
[Nm] Nome de substância:
0 (Iodine Radioisotopes); 0 (Sodium Chloride, Dietary); 0 (Thyroid Hormones); 0 (Trace Elements); 06LU7C9H1V (Triiodothyronine); 4W9K63FION (Dextrothyroxine); 9679TC07X4 (Iodine); E1UOL152H7 (Iron); EC 1.11.1.8 (Iodide Peroxidase)
[Em] Mês de entrada:0605
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:060418
[St] Status:MEDLINE


  7 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16444158
[Au] Autor:Ercan O
[Ad] Endereço:Istanbul University Cerrahpasa Medical Faculty, Department of Pediatrics, Istanbul, Turkey. oyaercan@istanbul.edu.tr
[Ti] Título:Thyroid Hormone Resistance in children.
[So] Source:Pediatr Endocrinol Rev;1 Suppl 2:191-8; discussion 198, 2003 Dec.
[Is] ISSN:1565-4753
[Cp] País de publicação:Israel
[La] Idioma:eng
[Ab] Resumo:Thyroid Hormone Resistance (RTH) is characterized by the diminished response of thyroid hormone-responsive tissues in varying degrees in association with elevated serum levels of total and free T4 and T3 and inappropriately normal or elevated TSH levels. In almost all cases it is due to different mutations in only one allele of the thyroid hormone receptor beta gene which blocks the action of normal allele thus producing dominantly inherited RTH. In RTH, varying degrees of target tissue responsiveness result in a heterogenous clinical presentation. Resistance in the thyrotrophs and the peripheral tissues is assessed by the evaluation of TSH secretion and changes in peripheral markers of thyroid hormone action after administration of L-T3, respectively. The treatment decision depends on the individual characteristics of each patient. Patients with hypothyroid and hyperthyroid symptoms may require treatment with thyroid hormone and with agents such as beta blockers, antithyroid drugs and thyroid hormone analogues.
[Mh] Termos MeSH primário: Síndrome da Resistência aos Hormônios Tireóideos
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Criança
Dextrotireoxina/uso terapêutico
Seres Humanos
Mutação
Fatores de Risco
Receptores beta dos Hormônios Tireóideos/genética
Síndrome da Resistência aos Hormônios Tireóideos/sangue
Síndrome da Resistência aos Hormônios Tireóideos/tratamento farmacológico
Síndrome da Resistência aos Hormônios Tireóideos/genética
Tireotropina/sangue
Tri-Iodotironina/análogos & derivados
Tri-Iodotironina/sangue
Tri-Iodotironina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Thyroid Hormone Receptors beta); 06LU7C9H1V (Triiodothyronine); 29OQ9EU4R1 (3,3',5-triiodothyroacetic acid); 4W9K63FION (Dextrothyroxine); 9002-71-5 (Thyrotropin)
[Em] Mês de entrada:0602
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060131
[St] Status:MEDLINE


  8 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10090317
[Au] Autor:Sarkissian G; Dace A; Mesmacque A; Bony-Trifunovic H; Malezet-Desmoulins C; Torresani J; Margotat A
[Ad] Endereço:INSERM U476 et U38, IFR 35, Université de la Méditerranée, Marseille, France.
[Ti] Título:A novel resistance to thyroid hormone associated with a new mutation (T329N) in the thyroid hormone receptor beta gene.
[So] Source:Thyroid;9(2):165-71, 1999 Feb.
[Is] ISSN:1050-7256
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Resistance to thyroid hormone (RTH) is a syndrome of elevated serum thyroxine, inappropriately "normal" serum thyrotropin (TSH) and reduced thyroid hormone responsiveness associated with point mutations in the thyroid hormone receptor-beta (TRbeta) gene. We describe a novel point mutation resulting in a cytosine for adenine substitution at nucleotide 1271 (exon 9) that results in the substitution of threonine for asparagine (T329N). This mutation was identified in a 30-year-old woman who was investigated for recurrent spontaneous abortions and was found to have RTH. Dextrothyroxine (D-T4) therapy was instituted. At 8 mg per day 2 pregnancies followed with the delivery of a healthy boy and an RTH-affected girl another miscarriage occurred on D-T4 treatment at 6 mg per day. The T329N mutation, which was also identified in the daughter, markedly reduces the affinity of TRbeta for triiodothyronine (T3). Formation of T329N mutant TR homodimers and heterodimers with RXRalpha on thyroid hormone response element F2 (TRE F2) was not affected, but the ability of T3 to interrupt T329N mutant TRbeta homodimerization was markedly reduced. The T329N mutant TRbeta was transcriptionally inactive in transient expression assays. In cotransfection assays with wild-type TRbeta1, the mutant TRbeta1 functioned in a dominant negative manner. The results suggest that the T329N mutation in the T3-binding domain of TRbeta is responsible for RTH in the proposita's family.
[Mh] Termos MeSH primário: Mutação Puntual
Receptores dos Hormônios Tireóideos/genética
Síndrome da Resistência aos Hormônios Tireóideos/genética
[Mh] Termos MeSH secundário: Aborto Habitual/genética
Adulto
Dextrotireoxina/uso terapêutico
Dimerização
Feminino
Seres Humanos
Masculino
Linhagem
Gravidez
Resultado da Gravidez
Receptores dos Hormônios Tireóideos/química
Receptores dos Hormônios Tireóideos/metabolismo
Análise de Sequência de DNA
Tireotropina/sangue
Tiroxina/sangue
Ativação Transcricional
Tri-Iodotironina/metabolismo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Receptors, Thyroid Hormone); 06LU7C9H1V (Triiodothyronine); 4W9K63FION (Dextrothyroxine); 9002-71-5 (Thyrotropin); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:9905
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990325
[St] Status:MEDLINE


  9 / 183 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9670962
[Au] Autor:Lin HY; Martino LJ; Wilcox BD; Davis FB; Gordinier JK; Davis PJ
[Ad] Endereço:Department of Medicine, Albany Medical College, NY 12208, USA.
[Ti] Título:Potentiation by thyroid hormone of human IFN-gamma-induced HLA-DR expression.
[So] Source:J Immunol;161(2):843-9, 1998 Jul 15.
[Is] ISSN:0022-1767
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We have investigated the mechanism by which thyroid hormone potentiates IFN-gamma-induced HLA-DR expression. IFN-gamma-induced HLA-DR expression requires activation of STAT1alpha and induction of the Class II trans-activator, CIITA. HeLa and CV-1 cells treated only with L-thyroxine (T4) demonstrated increased tyrosine phosphorylation and nuclear translocation (= activation) of STAT1alpha; this hormone effect on signal transduction, and T4 potentiation of IFN-gamma-induced HLA-DR expression, were blocked by the inhibitors CGP 41251 (PKC) and genistein (tyrosine kinase). Treatment of cells with T4-agarose also caused activation of STAT1alpha. In the presence of IFN-gamma, T4 enhanced cytokine-induced STAT1alpha activation. Potentiation by T4 of IFN-gamma action was associated with increased mRNA for both CIITA and HLA-DR, with peak enhancement at 16 h (CIITA), and 2 d (HLA-DR). T4 increased IFN-gamma-induced HLA-DR protein 2.2-fold and HLA-DR mRNA fourfold after 2 d. Treatment with actinomycin D after induction of HLA-DR mRNA with IFN-gamma, with or without T4, showed that thyroid hormone decreased the t(1/2) of mRNA from 2.4 to 1.1 h. HeLa and CV-1 cells lack functional nuclear thyroid hormone receptor. Tetraiodothyroacetic acid (tetrac) and 3,5,3'-triiodo-thyroacetic acid (triac) blocked T4 potentiation of IFN-gamma-induced HLA-DR expression and T4 activation of STAT1alpha. These studies define an early hormone recognition step at the cell surface that is novel, distinct from nuclear thyroid hormone receptor, and blocked by tetrac and triac. Thus, thyroid hormone potentiation of IFN-gamma-induced HLA-DR transcription is mediated by a cell membrane hormone binding site, enhanced activation of STAT1alpha, and increased CIITA induction.
[Mh] Termos MeSH primário: Antígenos HLA-DR/biossíntese
Interferon gama/farmacologia
Proteínas Nucleares
Tiroxina/farmacologia
[Mh] Termos MeSH secundário: Transporte Biológico/efeitos dos fármacos
Núcleo Celular/metabolismo
Dextrotireoxina/farmacologia
Di-Iodotironinas/farmacologia
Sinergismo Farmacológico
Genisteína/farmacologia
Antígenos HLA-DR/efeitos dos fármacos
Antígenos HLA-DR/genética
Células HeLa
Seres Humanos
Fator Gênico 3 Estimulado por Interferon
Fosforilação/efeitos dos fármacos
Proteína Quinase C/antagonistas & inibidores
Proteínas Tirosina Quinases/antagonistas & inibidores
RNA Mensageiro/efeitos dos fármacos
RNA Mensageiro/metabolismo
Tiroxina/análogos & derivados
Fatores de Tempo
Transativadores/genética
Fatores de Transcrição/efeitos dos fármacos
Fatores de Transcrição/metabolismo
Tri-Iodotironina/análogos & derivados
Tri-Iodotironina/farmacologia
Tri-Iodotironina Reversa/farmacologia
Tirosina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Diiodothyronines); 0 (HLA-DR Antigens); 0 (Interferon-Stimulated Gene Factor 3); 0 (MHC class II transactivator protein); 0 (Nuclear Proteins); 0 (RNA, Messenger); 0 (Trans-Activators); 0 (Transcription Factors); 0 (gamma interferon activation factor); 06LU7C9H1V (Triiodothyronine); 29OQ9EU4R1 (3,3',5-triiodothyroacetic acid); 42HK56048U (Tyrosine); 4W9K63FION (Dextrothyroxine); 534-51-0 (3,5-diiodothyronine); 5817-39-0 (Triiodothyronine, Reverse); 82115-62-6 (Interferon-gamma); DH2M523P0H (Genistein); EC 2.7.10.1 (Protein-Tyrosine Kinases); EC 2.7.11.13 (Protein Kinase C); PA7UX1FFYQ (tetraiodothyroacetic acid); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:9807
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:980722
[St] Status:MEDLINE


  10 / 183 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:9440092
[Au] Autor:Bommer C; Werle E; Walter-Sack I; Keller C; Gehlen F; Wanner C; Nauck M; März W; Wieland H; Bommer J
[Ad] Endereço:Medizinische Universitätsklinik, Heidelberg, Germany.
[Ti] Título:D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients.
[So] Source:J Am Soc Nephrol;9(1):90-6, 1998 Jan.
[Is] ISSN:1046-6673
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Uremia raises lipoprotein(a) (Lp(a)) serum concentration and the risk of arteriosclerosis in dialysis patients. The treatment of high Lp(a) levels is not satisfactory today. The decrease of Lp(a) in hypothyroid patients on L-T4 therapy raised the question of whether dextro-thyroxine (D-thyroxine) reduces not only serum cholesterol, but also Lp(a) serum concentration. In a single-blind placebo-controlled study, the influence of D-thyroxine therapy on Lp(a) serum concentration was evaluated in 30 hemodialysis patients with elevated Lp(a) serum levels. Lp(a) was quantified in parallel by two methods, i.e., rocket immunoelectrophoresis and nephelometry, and apo(a) isoforms were determined by a sensitive immunoblotting technique. Regardless of the apo(a) isoforms, 6 mg/d D-thyroxine reduced elevated Lp(a) levels significantly by 27 +/- 13% in 20 dialysis patients (P < 0.001) compared with 10 control subjects (-9.9 +/- 8.4%). In parallel, D-thyroxine therapy significantly lowered total cholesterol (P < 0.001), LDL cholesterol (P < 0.001), and LDL cholesterol/HDL cholesterol ratio (P < 0.01); raised T4 and T3 serum levels; and suppressed thyroid-stimulating hormone secretion without causing clinical symptoms of hyperthyroidism in any of the patients. D-Thyroxine reduces elevated serum Lp(a) concentration in dialysis patients. The effect in nondialysis patients can be expected but remains to be proven.
[Mh] Termos MeSH primário: Dextrotireoxina/uso terapêutico
Lipoproteína(a)/sangue
Diálise Renal
[Mh] Termos MeSH secundário: Idoso
Colesterol/sangue
Eletroforese
Feminino
Seres Humanos
Immunoblotting
Masculino
Meia-Idade
Nefelometria e Turbidimetria
Concentração Osmolar
Método Simples-Cego
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Lipoprotein(a)); 4W9K63FION (Dextrothyroxine); 97C5T2UQ7J (Cholesterol)
[Em] Mês de entrada:9803
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980124
[St] Status:MEDLINE



página 1 de 19 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde